Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea · Delayed Price · Currency is KRW 1,200.00
-1.00 (-0.08%)
Jul 1, 2026, 2:29 PM KST
Xcell Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -11,306 | -10,927 | -9,543 | -9,281 | -8,342 | -9,038 |
Depreciation & Amortization | 1,665 | 1,704 | 1,653 | 1,598 | 1,513 | 1,019 |
Loss (Gain) From Sale of Assets | -98.66 | -98.66 | 130.13 | -21 | 0.53 | 12 |
Asset Writedown & Restructuring Costs | - | - | - | 154.12 | - | - |
Loss (Gain) From Sale of Investments | - | -19.02 | -2.72 | 0.87 | - | - |
Loss (Gain) on Equity Investments | 1.14 | 0.81 | - | - | - | - |
Stock-Based Compensation | 70.12 | 127.83 | 228.31 | 283.67 | 540.12 | 354.46 |
Provision & Write-off of Bad Debts | -35.22 | 89.27 | 259.89 | 50 | - | - |
Other Operating Activities | 318.44 | 379.71 | 383.97 | 587.39 | 230.17 | 3,453 |
Change in Accounts Receivable | -180.2 | 72.06 | -31.37 | -301.81 | -104.98 | -133.14 |
Change in Inventory | -728.1 | -537.37 | 60.58 | -178.38 | -186.23 | 179.52 |
Change in Accounts Payable | 271.5 | 91.59 | 46.38 | 43.66 | -137.29 | -239.85 |
Change in Other Net Operating Assets | -617.06 | -385.34 | -180.91 | 280.29 | -808.69 | -211.69 |
Operating Cash Flow | -10,639 | -9,502 | -6,996 | -6,784 | -7,296 | -4,605 |
Capital Expenditures | -189.32 | -866.72 | -382.69 | -224.82 | -1,179 | -1,347 |
Sale of Property, Plant & Equipment | 165.05 | 165.05 | - | 55 | - | 0.45 |
Sale (Purchase) of Intangibles | -158.37 | -316.58 | -437.34 | -8.83 | -145.48 | -49.14 |
Investment in Securities | 2,622 | -3,771 | -1,780 | -3.96 | -131.88 | -3.88 |
Other Investing Activities | -17.64 | -17.64 | 1,328 | 4.06 | -10 | -259.51 |
Investing Cash Flow | 2,422 | -4,807 | -1,272 | -178.55 | -1,466 | -1,659 |
Long-Term Debt Issued | - | 700 | 1,950 | 350 | - | 3,000 |
Long-Term Debt Repaid | - | -1,395 | -3,035 | -587.44 | -455.54 | -759.28 |
Net Debt Issued (Repaid) | -722.75 | -695.48 | -1,085 | -237.44 | -455.54 | 2,241 |
Issuance of Common Stock | 9,170 | 9,220 | 15,875 | 3,000 | 16.66 | 8,092 |
Other Financing Activities | 119.04 | 119.13 | -0 | - | - | - |
Financing Cash Flow | 8,567 | 8,644 | 14,790 | 2,763 | -438.88 | 14,232 |
Foreign Exchange Rate Adjustments | -3.61 | -5.69 | 1,239 | 2.2 | 4.66 | 2.15 |
Net Cash Flow | 345.65 | -5,671 | 7,761 | -4,197 | -9,196 | 7,971 |
Free Cash Flow | -10,829 | -10,369 | -7,379 | -7,008 | -8,475 | -5,952 |
Free Cash Flow Margin | -410.05% | -532.01% | -381.48% | -623.58% | -830.82% | -302.69% |
Free Cash Flow Per Share | -817.91 | -889.87 | -737.48 | -792.48 | -968.02 | -718.67 |
Cash Interest Paid | 350.71 | 280.96 | 343.69 | 284.27 | 209.73 | 104.88 |
Cash Income Tax Paid | - | -11.26 | 23.06 | -8.31 | 11.26 | 3.73 |
Levered Free Cash Flow | -6,794 | -6,769 | -5,076 | -3,926 | -5,606 | -6,886 |
Unlevered Free Cash Flow | -6,792 | -6,766 | -5,074 | -3,924 | -5,604 | -6,774 |
Change in Working Capital | -1,254 | -759.05 | -105.33 | -156.23 | -1,237 | -405.17 |